Annals of Case Reports and Clinical Studies (ISSN: 2834-5673) | Volume 5, Issue 4 | Case Report | Open Access
: Marshall Deltoff*
Amit Korektor, Vladimir Tarci, Marshall Deltoff* and Haim Shtarker
Department of Orthopedics, Galilee Medical Center, Nahariya, Israel
*Correspondence to: : Marshall Deltoff
Fulltext PDFBackground: Topical autologous blood clot therapy is a localized care intervention that utilizes an autologous coagulum to promote reconstitution of the extracellular matrix within chronic or non-healing wounds. The clot functions as a bioactive scaffold enriched with intrinsic growth factors, cytokines, and chemokines that orchestrate cellular recruitment, angiogenic signaling, fibroblast activation, and regulated matrix deposition. In this study, we attempted to demonstrate the therapeutic effectiveness of ActiGraft in the management of complex chronic wounds occurring in patients with underlying diabetic comorbid conditions.
Methods: Chronic, non-healing diabetic foot wounds were treated using Red Dress ActiGraft technology. Local wound debridement was performed weekly in the outpatient clinic, followed by application of the autologous whole-blood clot. Wound-healing progression was documented through serial photographs, quantitative measurements of wound dimensions, and systematic recording of time to closure, continuing until complete epithelialization was achieved.
Results: The therapy demonstrated high clinical efficacy: five patients achieved complete wound closure, while the remaining two exhibited active epithelialization and a reduction in wound area exceeding 95%. No complications, infections, or adverse reactions attributable to the blood-clot application were observed in any patient.
Conclusions: ActiGraft offers an effective and safe therapeutic option for difficult-to-heal diabetic foot wounds, providing a biologically active scaffold that supports natural wound repair. These findings suggest that ActiGraft can play a valuable role in advanced diabetic foot wound management, particularly for patients who have not responded to conventional therapies.
Blood clot; Diabetic foot; Chronic wound; ActiGraft
Amit Korektor, Vladimir Tarci, Marshall Deltoff, Haim Shtarker. Autologous Whole-Blood Clot Therapy for Refractory Diabetic Foot and Ankle Wounds: Preliminary Clinical Findings. Ann Case Rep Clin Stud. 2026;5(4):1-16.